Pharmacokinetics of Two Different Formulations of Finasteride (Topical and Oral) in Male Volunteers with Androgenic Alopecia

The study aimed to compare the pharmacokinetic profiles of finasteride in male volunteers with androgenetic alopecia using two different formulations: a topical 0.25% solution and a 1 mg oral tablet. Conducted in Switzerland, the study involved 24 male participants aged 18-65, divided into two groups of 12 each. One group received the topical solution twice daily, while the other received the oral tablet once daily, both for 7 days. The study found that the topical formulation maintained a balanced amount of finasteride on the scalp, potentially allowing better penetration to the hair follicles. The study also monitored plasma levels of finasteride, testosterone, and dihydrotestosterone, as well as adverse events, which included known side effects such as decreased libido and erectile dysfunction. The study concluded without foreseeing real potential benefits for the volunteers, as it was a phase I trial primarily focused on safety and pharmacokinetics.